Patient-Reported Outcomes From Virologically Suppressed Adults Living With HIV-1 Switching to Once-Weekly Oral Islatravir in Combination With Ulonivirine: Phase 2b Week 24 Results

Conference Reports for NATAP

IDSA
ID Week 2026
October 21-24
Washington, DC


Patient-Reported Outcomes From Virologically Suppressed Adults Living With HIV-1 Switching to Once-Weekly Oral Islatravir in Combination With Ulonivirine: Phase 2b Week 24 Results

	IDSA 2026 Wash DC Oct 21-26 IDWeek2026: Efficacy and Safety of Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) or Standard of Care (SOC) in People With HIV-1 (PWH) and Virologic Suppression: Week 48 Integrated Analysis From the Phase 3 ISLEND-1 and ISLEND-2 Trials - (10/24/26)